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Abstract
Accumulating evidence indicates that epithelial cancer cells, including nasopharyngeal carcinoma (NPC) cells, express
immunoglobulins (Igs). We previously found that the expression of the kappa light chain protein in NPC cells can be
upregulated by the EBV-encoded latent membrane protein 1 (LMP1). In the present study, we used NPC cell lines as models
and found that LMP1-augmented kappa production corresponds with elevations in ERKs phosphorylation. PD98059
attenuates LMP1-induced ERKs phosphorylation resulting in decreased expression of the kappa light chain. ERK-specific
small interfering RNA blunts LMP1-induced kappa light chain gene expression. Luciferase reporter assays demonstrate that
immunoglobulin k 39 enhancer (39Ek) is active in Igk-expressing NPC cells and LMP1 upregulates the activity of 39Ek in NPC
cells. Moreover, mutation analysis of the PU binding site in 39Ek and inhibition of the MEK/ERKs pathway by PD98059
indicate that the PU site is functional and LMP1-enhanced 39Ek activity is partly regulated by this site. PD98059 treatment
also leads to a concentration-dependent inhibition of LMP1-induced Ets-1 expression and phosphorylation, which
corresponds with a dose-dependent attenuation of LMP1-induced ERK phosphorylation and kappa light chain expression.
Suppression of endogenous Ets-1 by small interfering RNA is accompanied by a decrease of Ig kappa light chain expression.
Gel shift assays using nuclear extracts of NPC cells indicate that the transcription factor Ets-1 is recruited by LMP1 to the PU
motif within 39Ek in vitro. ChIP assays further demonstrate Ets-1 binding to the PU motif of 39Ek in cells. These results
suggest that LMP1 upregulates 39Ek activity and kappa gene expression by activating the Ets-1 transcription factor through
the ERKs signaling pathway. Our studies provide evidence for a novel regulatory mechanism of kappa expression, by which
virus-encoded proteins activate the kappa 39 enhancer through activating transcription factors in non-B epithelial cancer
cells.
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Introduction
The restriction of immunoglobulin (Ig) expression to cells of the
B-cell lineage is well established. However, we found Ig kappa light
chain was ‘‘unexpectedly’’ expressed in epithelial cancer cell lines
and epithelial tissues [1,2,3]. The expression of Ig kappa light
chain in non-hematopoietic tumor cell lines was also reported by
other laboratories [4,5,6,7].
Immunoglobulin kappa light chain gene expression is under the
control of distinct cis-regulatory elements, including promoters
and enhancers. Two important kappa enhancers: the intronic
enhancer (iEk), which lies between the Jk-Ck region, and the 39
enhancer (39Ek), which is located downstream of the Ck region,
have been identified [8,9,10]. Both enhancers are inactive at the
pro-B and pre-B cell stages and active at the Igk-expressing
mature B cell and plasma cell stages [10,11]. The activity of these
enhancers is generally transcriptionally silent in other cells that
cannot produce the kappa chain, such as T-lymphoid cells (Jurkat)
[10], epithelial cells (HeLa) [10] and NIH3T3 fibroblasts [12].
Based on these observations, the activation of these regulatory
elements is generally believed to be required for immunoglobulin
kappa gene expression and is a B cell lineage-restricted event [10].
Intriguingly, we have found that human iEk is active in Igk-
expressing nasopharyngeal carcinoma (NPC) cell lines, which is
important for kappa light chain expression in these cells [13].
However, whether the other kappa enhancer, 39Ek, is functional in
Igk-expressing epithelial cancer cells remains unknown.
The function of enhancers is mediated by DNA binding
proteins that are recruited to the regulatory elements of the
enhancers. Several positive regulatory elements have been
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(TTTGGGGAA) for transcription factor Ets-related proteins
[10]. The Ets family comprises several subfamilies, including
ETS (Ets-1, Ets-2), TCF (Elk-1, Sap-1, etc.), and SPI (PU.1, Spi-B,
Spi-C etc.). Family members are identified on the basis of their
structural composition and their similarities in the evolutionarily-
conserved Ets domains that mediate binding to purine-rich DNA
sequences with a central GGAA/T core consensus [14,15]. Ets
family proteins are nuclear proteins and phosphorylation is an
important post-translational modification of many Ets family
members, which can affect their transcriptional activities and
DNA-binding activities [15]. In B cells, binding of the PU.1
protein to the kappa 39 enhancer play an important role in 39Ek
function [16]. Phosphorylation of PU.1 at Ser148 is required for
the interaction of PU.1 with Pip on DNA and this phosphorylation
can regulate the transcriptional activity of PU.1 [17]. However,
the PU.1 protein is exclusively expressed in hematopoietic cells
[15,18] and is unlikely to execute regulatory function in Igk-
expressing epithelial cancer cells. Recent study by using chromatin
immunoprecipitation coupled with genome-wide promoter micro-
arrays to query the occupancy of three ETS proteins in a human
T-cell line, revealed that redundant occupancy was frequently
detected, while specific occupancy was less likely [19]. Thus, we
can speculate that, If 39Ek is indeed functional in Igk-expressing
epithelial cancer cells, other Ets family proteins are more likely to
play a role in 39Ek activity than PU.1. Therefore, we decided to
further investigate that which transcription factor(s) bound to the
PU binding site of 39Ek and whether the binding is important for
39Ek functional activation in Ig kappa-expressing epithelial cancer
cells.
Our previous study showed that the kappa light chain gene was
expressed in NPC and other epithelial tumor cells. Most
interestingly, we found that the levels of the kappa light chain
were substantially higher in LMP1-positive cells compared to
LMP1-negative cells [2]. Because of its transforming and
tumorigenic activities, LMP1 is considered to be a major
oncogenic protein encoded by EBV. LMP1 mediates a variety of
cellular signaling pathways including NF-kB, c-Jun-NH2-terminal
kinases (JNKs), p38/MAPK, PI3K/Akt and JAK/STAT and
causes transcriptional upregulation of several cellular genes, such
as il-6, il-8, bcl-2, cd23, a20 and egfr [20,21,22]. LMP1 can also
activate the Ras/ERK/MAPK signaling pathway [23], and the
Ras/MAPK signaling kinases, Raf, MEK and ERKs, are activated
in LMP1-expressing nasopharyngeal epithelial cells [24]. More-
over, Kim [25] reported that stable transfection of the LMP1 gene
into MDCK cells induced expression of Ets-1, suggesting that Ets
might be a target gene of LMP1. As mentioned above, Ets-1 and
Ets-2 are subfamily members of Ets-related proteins. Both of them
are nuclear targets of the Ras signaling pathway and phosphor-
ylation of conserved threonine residues, Thr38 and Thr72, is a
necessary molecular event for Ras-mediated activation of these
transcription factors [26]. Cumulatively, an LMP1/ERK/Ets/
kappa signaling cascade might exist by which LMP1 upregulates
kappa light chain expression in NPC cells.
In the present study, The MEK inhibitor, PD98059, was used to
investigate the role of the ERKs pathway in LMP1-enhanced
kappa light chain production in NPC cells. The data presented
here demonstrate that LMP1-augmented kappa production
corresponds with elevations in ERKs phosphorylation. PD98059
inhibits LMP1-induced ERKs phosphorylation resulting in
decreased expression of the kappa light chain. ERK-specific small
interfering RNA blunts LMP1-induced kappa light chain gene
expression. Luciferase reporter assays demonstrate that 39Ek is
active in Igk-expressing NPC cells and stable LMP1 expression
upregulates the activity of 39Ek in NPC cells. Mutations of the PU
binding site on 39Ek significantly decrease LMP1-enhanced 39Ek
activity. LMP1-induced 39Ek activity is dramatically inhibited by
the ERKs upstream kinase inhibitor, PD98059. Treatment of
PD98059 also leads to a concentration-dependent inhibition of
LMP1-induced Ets-1 expression and phosphorylation, which
corresponds with a dose-dependent attenuation of LMP1-induced
ERK phosphorylation and kappa light chain expression. The
knockdown of endogenous Ets-1 by small interfering RNA is
accompanied by a decrease of Ig kappa light chain expression. Gel
shift assays using nuclear extracts prepared from various NPC cell
lines confirm that the transcription factor Ets-1 is recruited by
LMP1 to the PU motif of the human kappa light chain gene. ChIP
assays further demonstrate that Ets-1 directly binds to the PU
motif of 39Ek in cells. These results suggest that LMP1 upregulates
39Ek activity and kappa light chain gene expression by activating the
Ets-1 transcription factor through the ERKs signaling pathway.
Materials and Methods
Cell lines and cell culture
HNE2 is an EBV-LMP1-negative human NPC cell line. HNE2-
LMP1 is a cell line that constitutively expresses LMP1 after the
introduction of full-length LMP1 cDNA into HNE2 cells [27]. The
human myeloma cell lines, XG6, which expresses the cytoplasmic
l light chain, and XG7 that expresses the cytoplasmic k light
chain [28], were used as kappa chain negative and positive
controls, respectively. Raji is a human B-cell Burkitt’s lymphoma
cell line. All the cell lines were maintained in RPMI1640 (GIBCO,
USA) supplemented with 10% FBS (GIBCO, USA), 1%
glutamine, and 1% antibiotics in a 37uC humidified atmosphere
containing 5% CO2. For the XG6 and XG7 cells, 1 ng/ml rIL-6
(Sigma, St. Louis, MO) was added to RPMI1640 medium
supplemented as described above [28]. Cells in logarithmic growth
phase were used in all experiments.
Chemicals and cell treatments
The ERKs upstream kinase MEK inhibitor, PD98059 (Cell
Signaling, USA), was prepared as a stock solution of 20 mM in
dimethylsulfoxide (DMSO, Sigma). Subconfluent cells were
treated with the compound at various concentrations for different
times. Detailed treatment procedures are described in the Figure
Legends. The final concentration of DMSO in the culture medium
was kept at less than 0.1%, which had no significant effect on cell
growth. Vehicle controls were prepared for all treatments.
Plasmids
The human b-globin promoter was a 128 bp minimal promoter
identical to that used previously [29]. The promoter was obtained
by amplification from human HNE2 cellular genomic DNA with
the following primers: sense, 59-gagctcacggctgtcatcacttagacctcac-39,
which contains the Sac I cloning site; antisense, 59-aagctttaagcaa-
tagatggctctgccctgac-39, which contains the Hind III site. The
fragment was inserted into the Sac I/Hind III sites of the pGL3-Basic
vector (Promega, Madison, WI) and the plasmid was designated as
pGL3-b.
A 313 bp fragment containing the human 39Ek enhancer core
and 90 bp upstream of the enhancer core sequences [10,30,31]
was cloned. The 39Ek enhancer fragment was amplified from
HNE2 cellular genomic DNA by PCR using specific primers from
the human Ig kappa gene (GenBank accession no. NG_000834):
sense, 59-ggatcccctcttggtaccccagcata-39, which contains an artificial
BamH I site; antisense, 59- gtcgacctgaaagggtgtggagtgct-39, which
contains an artificial Sal I site. The PCR-amplified fragments were
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corresponding restriction sites of the pGL3-b plasmid described
above to generate pb-39Ekwt. The PCR products were confirmed
by their size, as determined by electrophoresis and by DNA
sequencing. The PU motif mutant (designated as pb-39Ekmt) from
pb-39Ekwt was generated by PCR based on an overlap extension
technique [32]. The primers used for generating mutations were:
forward, 59-accctttgggcccctgaaaacagaacc-39; reverse, 59-
ttttcaggggcccaaagggtcttctcc-39. The PCR-amplified fragments
carrying the desired mutations were then cloned into the BamH
I/Sal I sites of the pGL3-b plasmid. The expected mutations and
the integrity of the enhancer were confirmed by automated
sequencing using an Applied Biosystems sequencer and software
(Foster City, CA).
RNA interference
HNE2-LMP1 cells were grown in 6-well plates and transfected
with an ERK-specific small interfering RNA oligonucleotide (si-
ERK; Cat no: #6560; 100 pmol; Cell Signaling) or scrambled
oligonucleotides (si-scrambled; Cat no: #6568;100 pmol; Cell
Signaling); an Ets-1-specific small interfering RNA oligonucleotide
(si-Ets-1; Cat no: sc-29309; 150 pmol; Santa Cruz) or scrambled
oligonucleotides (si-scrambled; Cat no: sc-37007; 150 pmol; Santa
Cruz) using Lipofectamine
TM 2000 (Invitrogen, USA) for 72 hr
according to the manufacturer’s instructions. To confirm ERK or
Ets-1 knockdown, cells transfected with si-ERK, si-Ets-1, or
scrambled oligonucleotide were harvested for protein extraction
and immunoblotting.
Luciferase reporter assays
The pGL3-b,p b-39Ekwt and pb-39Ekmt firefly luciferase reporter
plasmids described above were used in conjunction with the
control pGL3-Basic vector (Promega) and the internal control
plasmid pRL-SV40 (Promega). Cells were cultured in 24-well plates
at a density of 1610
5 per well overnight and then transfected with
the indicated plasmid using Lipofectamine
TM 2000 (Invitrogen)
following the manufacturer’s instructions. Each transfection
contained 800 ng/well of the firefly luciferase reporter plasmid
and 80 ng/well of the internal control pRL-SV40 plasmid. At 24 hr
after transfection, cells were either left untreated or treated with
50 mM PD98059 or 0.1% DMSO for 12 hr. Cells were harvested
at 36 hr after transfection and lysates were analysed for firefly and
renilla luciferase activity according to the manufacturer’s instruc-
tions using the Dual-Luciferase Reporter Assay Kit (Promega) with
a GloMax 20/20 luminometer (Promega). The luciferase reporter
plasmids were co-transfected with the pRL-SV40 vector to correct
for variations in transfection efficiency. The data are represented
as the fold induction compared to the pGL3-Basic vector. At least
three independent transfection experiments were performed in
triplicate for each experimental construct.
Reverse transcription and polymerase chain reaction
Subconfluent HNE2 and HNE2-LMP1 cells were treated or not
treated with 50 mM PD98059 for 12 hr. Total RNA was isolated
from the cells, including XG6, XG7 or Raji cell lines as controls,
using the TRIzol reagent (Invitrogen) according to the instructions
of the manufacturer. RNA was dissolved in 20 ml of DEPC-treated
water and quantified at 260 nm. Total RNA (2 mg) was reverse
transcribed with SuperScript
TM IIRT (Invitrogen) at 42uC for
50 min, and the resulting cDNA was subjected to PCR. For kappa
light chain RT-PCR, in order to determine the optimal PCR cycle
number, a constant amount of input cDNA was used in PCR
reactions, the cycle number was varied between 25 and 40 (25, 28,
32, 36, 38, 40) and the PCR product of 36 cycles showed a good
detectable signal and was in the linear range. The cycling
conditions for human kappa light chain (GenBank accession
no. AJ010442) or for actin:9 4 uC for 5 min followed by 36 cycles
of 94uC for 30 sec, 50uC for 30 sec, 72uC for 30 sec, and an
extension for 10 min at 72uC. PCR thermocycling conditions for
Ets family members, LMP1 and GAPDH are 95uC for 5 min
followed by 32 cycles of 95uC for 30 sec, 55uC for 30 sec, 72uC for
40 sec, and an extension for 10 min at 72uC. For quantitative real-
time RT-PCR (qRT-PCR), iTaq SYBR Green Supermix with
Rox (Cat. no. 172-5850, Bio-Rad) was used with the following
cycling conditions: 95uC for 10 min, then 40 cycles of 95uC for
15 sec followed by 60uC for 1 min in an ABI Prism 7500
Sequence Detection System (Applied Biosystems). The relative
mRNA expression levels were calculated according to the
comparative CT (DDCT) method after normalizing to GAPDH
expression. Primer sequences for amplification of Ig kappa light
chain, Ets family members [33], LMP1 [34] and internal controls
are listed in Table S1. PCR products were separated on 1.5–2%
agarose gels and visualized with ethidium bromide.
Protein extraction
Whole-cell lysates were essentially prepared according to a
method previously described [2]. For the electrophoresis mobility
shift assays (EMSAs), nuclear extracts were prepared using the
NE-PER Nuclear and Cytoplasmic Extraction Kit (Cat.
no. 78833, Pierce, USA) following the manufacturer’s instructions.
Protein concentration was determined using the BCA Assay
Reagent (Cat. no. 23228, Pierce).
Western blot analysis
Proteins (50 to 100 mg) were boiled in SDS sample buffer for
5 min, resolved on 10% SDS-polyacrylamide gels and transferred
onto a nitrocellulose membrane (Millipore, USA). Nonspecific
reactivity was blocked by incubating the membrane for 30 min in
a Tris-buffered saline solution containing 0.1% Tween-20 and
10% nonfat dried milk. The membrane was incubated overnight
at 4uC with various primary antibodies, followed by incubation at
room temperature for 1 hr with a horseradish peroxidase-
conjugated mouse or rabbit secondary antibody (Santa Cruz,
USA), and then washed three times for 10 min each with Tris-
buffered saline containing 0.1% Tween-20. The antibody-bound
proteins were detected using an enhanced chemiluminescence
detection kit (Cat. no. 34075, Pierce) followed by exposure to
autoradiographic film. After probing for phosphorylated ERKs or
phosphorylated Ets-1 to examine ERKs activation status or the
level of phosphorylated Ets-1, membranes were stripped by
incubating at 50uC for 30 min in stripping buffer (100 mM b-
mercaptoethanol, 2% (wt/vol) sodium dodecyl sulfate and
62.5 mM Tris-HCl pH 6.8) and reprobed with anti-ERK or
anti-Ets-1. The following antibodies were used for Western
blotting: mouse anti-LMP1 monoclonal antibody (CS.1–4,
DAKO, Denmark), rabbit anti-human kappa light chain antibody
(A0191, DAKO), Ets-1 (sc-350), phosphorylated threonines (sc-
5267), ERK (sc-93), phosphorylated ERK (sc-7383), and a-tubulin
(sc-5286) (all from Santa Cruz).
Immunoprecipitation
Whole-cell lysates (200 mg) were mixed with protein A-
Sepharose beads (Sigma), incubated at 4uC for 2 hr, and
centrifuged for 2 min at 2,000 rpm for preclearing. Then the
supernatant fraction was incubated at 4uC overnight with 4 mgo f
an Ets-1 antibody and protein A-Sepharose beads, followed by
centrifugation for 2 min at 12,000 rpm. The immunoprecipitates
were collected and washed five times with PAPI buffer (50 mM
Mechanism of Igk Expression in Cancer Cells
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sodium deoxycholate, 1 mM EDTA, 150 mM NaCl, and protease
inhibitors). The precipitates were eluted from the protein A-
Sepharose beads by boiling for 5 min and finally subjected to
Western blot analysis using an antibody to detect threonine
phosphorylation.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSAs) were conducted
using the LightShift
TM Chemiluminescent EMSA Kit (Cat.
no. 20148, Pierce) following the manufacturer’s instructions. The
protein concentration in nuclear extracts was determined using the
BCA protein assay reagent (Cat. No. 23228, Pierce) and EMSAs
were performed using aliquots containing equal amounts of
protein. The reaction mixtures (20 ml) containing nuclear extracts
(8 mg) were incubated with biotin-labeled double-stranded oligo-
nucleotide probes (2 nM) in reaction buffer (Pierce) for 20 min at
room temperature. Reactions were subjected to electrophoresis on
5% polyacrylamide gels in 0.56 Tris-borate-ethylene diamine
tetra-acetic acid (TBE) buffer followed by electroblotting onto
Biodyne
TM B Nylon membranes (Cat. no. 77016, Pierce) and UV
cross-linking. Biotinylated oligonucleotides were then detected by
probing with streptavidin conjugated to HRP and visualized using
an ECL kit and autoradiography. For competition analyses, a 100-
fold excess of the corresponding unlabeled wild-type oligo or the
mutant oligo was included in the binding reaction. For antibody
supershift experiments, the reaction mixtures were preincubated
with 2 mg of an Ets-1 (sc-350X, Santa Cruz) antibody at room
temperature for 1 hr. The complementary oligonucleotides used
as probes or competitors are as follows: wild-type human kPU
oligonucleotides, 59- gaagaccctttggggaactgaaaacaga-39 and 59-
tctgttttcagttccccaaagggtcttc-39, derived from the sequence of the
PU site within the human 39Ek. The mutated kPU oligonucleo-
tides (designated as mutPU) used were 59-gaagaccctttgggcccct-
gaaaacaga-39 and 59-tctgttttcaggggcccaaagggtcttc-39. The non-
specific competing probes were 59-ccagagggggatttccaagaggcca-39
and 59-tggcctcttggaaatccccctctgg-39, which were derived from the
sequence of the NF-kB site within the human iEk. Binding sites are
underlined and mutations are shown in bold type. The mutated
oligo probes against the kPU binding site for EMSAs are identical
to those of the mutated sequences in the reporter gene constructs.
Chromatin immunoprecipitation (ChIP) assay
ChIP analysis was performed using a ChIP assay kit (Upstate
Biotechnology, Lake Placid, NY) according to the manufacturer’s
recommendations. Briefly, a formaldehyde solution was added
directly to HNE2-LMP1 cells at a final concentration of 1% and
incubated at room temperature for 10 min. Then the cells were
neutralized for 5 min with glycine at room temperature and
washed twice with ice-cold 16phosphate-buffered saline contain-
ing protease inhibitors. The cells were disrupted using SDS lysis
buffer containing protease inhibitors. Chromatin in the lysate
(350 ml) was sheared to an average length of ,500 bp by
sonication with a Branson Sonifier Cell Disruptor B15 (output
control 4, duty cycle 40%), with 14 cycles of 20-sec pulses at 20-sec
intervals. The suspension was precleared in a salmon sperm
DNA/protein A/agarose-50% slurry for 1 hr at 4uC. After the
chromatin was ‘‘precleared’’, a small aliquot (10 ml) was saved as
‘‘input DNA’’ for PCR analysis later. The remaining aliquots
(100 ml each) of sheared cross-linked chromatin were incubated
overnight with 2 mg Ets-1 (sc-350X), rabbit IgG (sc-2027) (Santa
Cruz), or no antibody at 4uC with mild shaking. The immune
complexes were incubated for 2 hr at 4uC in a salmon sperm
DNA/protein A/agarose-50% slurry with mild shaking, washed,
and eluted. Cross-linking was reversed using 5 M NaCl. After
proteinase K digestion, the DNA in the samples was extracted with
phenol, precipitated with ethanol, and resuspended in 50 mlo f
ddH2O. The DNA solution (2 ml) was used for 36 cycles of PCR
amplification. PCR products were analyzed by electrophoresis on
a 2% agarose gel and visualized by ethidium bromide staining.
The following primers were used in the ChIP assays: human 39Ek
enhancer including the PU-binding region, 59- ccagggaccaaga-
tagcaac -39 and 59- ctgaaagggtgtggagtgct -39 (158 bp).
Statistical analysis
All statistical calculations were performed using the SPSS (v.
12.0) statistical software program. Differences between various
groups were evaluated by the Student’s t test. The difference was
statistically significant when p,0.05.
Results
LMP1 enhances kappa light chain expression through the
ERKs signaling pathway in human NPC cells
LMP1 can activate the Ras/ERK/MAPK signaling pathway
[23] and our previous study indicated that LMP1 upregulates
kappa light chain expression in NPC cell lines [2]. To confirm
whether ERKs pathway is involve in LMP1-augmented kappa
light chain expression, PD98059 was used to manipulate ERKs
activation and kappa chain upregulation induced by LMP1. The
level of ERK phosphorylation was higher in HNE2-LMP1 cells
than in HNE2 cells, which demonstrated that LMP1 indeed
activates the ERK pathway in NPC cells (Figure 1A). Treatment of
HNE2-LMP1 cells with PD98059 resulted in a dose-dependent
suppression of LMP1-induced kappa light chain (Figure 1B),
which corresponded with a dose-dependent attenuation of ERK
phosphorylation induced by LMP1 (Figure 1A). PD98059 (50 mM)
clearly showed an inhibitory effect on HNE2-LMP1 cells, but had
no effect on HNE2 cells (Figure 1C). In order to determine if the
inhibition of Ig kappa expression by PD98059 treatment occurs at
the transcriptional level, HNE2 and HNE2-LMP1 cells were
maintained under the same conditions and the levels of kappa light
chain mRNA were examined by RT-PCR. Treatment with
PD98059 (50 mM) induced a marked decrease in LMP1-induced
kappa mRNA expression, but the kappa mRNA level in HNE2
remained essentially unchanged (Figure 1D), which agrees with the
immunoblot results. To further confirm that the ERK pathway
plays a role in LMP1-induced kappa light chain gene expression, we
knocked down ERK expression by RNA interference. Whereas
transfection of HNE2-LMP1 cells with a scrambled oligonucleo-
tide did not affect LMP1-induced kappa gene expression, si-ERK
blunted the effect of LMP1 (Figure 1E), indicating that the ERK
pathway is involved in this event. Overall, these results confirm the
idea that upregulation of kappa light chain by LMP1 occurs
through the activation of the ERK/MAPK signaling pathway.
The PU binding site is involved in LMP1-enhanced
activity of 39Ek through the ERK pathway
The activation of the 39Ek is required for immunoglobulin kappa
gene expression. In order to investigate whether 39Ek could be
functionally activated in NPC cells, we linked a 313 bp human
39Ek enhancer fragment, which contains the enhancer core and
90 bp upstream of the enhancer core sequences that is necessary
for maximal enhancer activity when the enhancer core is not
directly adjacent to the promoter [31], to the human b-globin
promoter to drive expression of the firefly luciferase gene and
analyzed this reporter construct by transient transfection of NPC
cell lines (Figure 2A, B). The human b-globin promoter was chosen
Mechanism of Igk Expression in Cancer Cells
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immunoglobulin enhancers [35,36,37], and also because we found
it to be minimally affected by LMP1 in our experiments (Figure 2C
and Figure 3). The constructs were introduced into HNE2 and
HNE2-LMP1 cells to test the activity of 39Ek. Transfection of pb-
39Ekwt generated higher luciferase activity than transfection of the
pGL3-b construct (no enhancer), regardless of whether LMP1-
negative (p,0.05) or LMP1-positive (p,0.01) NPC cells were
examined. These results indicated that 39Ek is active in NPC cells
that expressed the Ig kappa light chain. Moreover, the activity of
39Ek in HNE2-LMP1 cells was approximately 3-fold higher than
that in HNE2 cells (p,0.05) (Figure 2C), which agreed with the
kappa chain expression patterns of these two cell lines [2].
Notably, the luciferase activity of pGL3-b in both HNE2 and
HNE2-LMP1 cells was essentially equivalent, which suggested that
the difference in the 39Ek activity between HNE2 and HNE2-
LMP1 cells was due to the enhancer itself rather than the
promoter sequence. These results indicate that 39Ek is active in Ig
kappa-expressing NPC cells and LMP1 elevates the activity of
39Ek, which might account for the upregulation of the kappa light
chain protein by LMP1 in NPC cells.
PU motif (TTTGGGGAA) is one of positive regulatory
elements that modulate kappa light chain expression in B cells
[10]. To confirm the role of this element in regulating kappa light
chain expression in NPC cells, site-directed mutagenesis by
overlap extension PCR was used to introduce mutations into the
consensus PU motif for the family of transcription factor Ets-
related proteins within 39Ek. The pb-39Ekmt construct was created
and used to test the activity of 39Ek. Mutation of the PU motif
significantly (p,0.05) decreased LMP1-increased 39Ek activity
(Figure 2C). In contrast, the 39Ek activity in HNE2 cells was
slightly decreased by this genetic manipulation. This result and the
result showing that mutation of the PU motif could not completely
abolish 39Ek activity in HNE2-LMP1 cells, as well as previous
reports indicating that several additional functional motifs reside
within 39Ek [10,11], suggest that a variety of nuclear factors can
bind to 39Ek resulting in highly complex regulatory pathways.
Together, the results indicated that the PU binding site contributes
to the 39Ek-mediated kappa light chain gene transcriptional
activation.
To further confirm that the LMP1-induced transcriptional
enhancement effect on 39Ek is ERK-mediated, we used the ERK
upstream kinase inhibitor, PD98059, to block ERK signaling and
test 39Ek activity. LMP1-induced activity of 39Ek was dramatically
inhibited (p,0.05) by PD98059 (50 mM, Figure 3). The inhibitory
effect of PD98059 on LMP1-induced 39Ek activity was more
robust than the inhibition resulting from the mutation in the PU
binding site (Figure 2C and Figure 3). One possible explanation for
this observation is that other transcription factors that regulate
39Ek activity are likely ERK-targeted substrates, which can be
simultaneously inhibited by PD98059. This compound also
decreased 39Ek activity in HNE2 cells to a certain extent, but
the decrease was not statistically significant (p.0.05), which is
consistent with the immunoblot (Figure 1C) and RT-PCR
(Figure 1D) results shown earlier. We speculated that PD98059
can not reduce the basal activity of ERKs as did NF-kB inhibitor
Bay11-7082, which was reported that did not reduce the basal
activity of an NF-kB [38]. This could explain why PD98059 had
no obvious effect on HNE2 cells. The transcriptional activities of
the human b-globin promoter were slightly decreased by PD98059
in both LMP1-negative and LMP1-positive NPC cells. Based on
these results, we concluded that the PU binding site contributes to
LMP1-increased 39Ek activity as well as kappa light chain gene
expression and these events are mediated by ERK signaling.
Ets family gene expression in human NPC cell lines
To characterize which Ets family member bound to PU motif in
human NPC cells, we first analyze Ets family gene expression in
these cell lines. There are 27 Ets genes in the human genome.
Genome-wide analyses reveal properties of redundant within the
Ets gene family members [19]. We tested mRNA level of Ets gene
family members, including those that are classified as ubiquitous or
cell-type-specific expressions [33]. The RT-PCR results showed
that two hematopoietic tissue-specific Ets transcription factors
PU.1 and Spi-B, which are important for B cell maturation, were
highly expressed in Raji cells but were not detectable in two NPC
cell lines. Consistent with previous report [33], mRNA levels of
E1AF, ESE1, TEL2 and PDEF in Raji cells were too low to be
detected. In addition, RT-PCR results showed that the mRNA
levels of Ets-1, E1AF and ERM were higher in HNE2-LMP1 cells
than those in HNE2 cells. Other Ets family members assessed,
such as Elf-1, Elk-1, Sap-1, showed no significant difference at
mRNA levels between HNE2 and HNE2-LMP1 cells (Figure 4A).
We also performed quantitative real-time RT-PCR to compare
mRNA levels of Ets-1, Ets-2, E1AF and ERM genes between
HNE2 and HNE2-LMP1 cells. As shown in Figure 4B, higher
mRNA levels of Ets-1, E1AF and ERM in HNE2-LMP1 cells,
about a 2-fold increase for Ets-1 as well as 5-fold increases for
E1AF and ERM, compared with HNE2 cells. No significant
difference of Ets-2 mRNA level between HNE2 and HNE2-LMP1
cells. The Ets-2 mRNA expression pattern in HNE2 and HNE2-
LMP1 cells was in accordance with a previous report that the level
of Ets-2 protein was unaffected by LMP1 [39]. The result
indicated that LMP1 induced Ets-1, E1AF and ERM expression at
mRNA level.
Upregulation of kappa light chain expression by LMP1
occurs through ERK-mediated Ets-1 phosphorylation and
activation
Ets-1 is a nuclear target of the Ras signaling pathway and
contains an ERK MAP kinase docking site [26,40]. The
phosphorylation of Ets-1 is a necessary molecular event for Ras-
mediated activation of this transcription factor [26]. To investigate
whether the transcription factor Ets-1 plays an important role in
Figure 1. Inhibition of the ERKs signaling pathway blunts LMP1-increased kappa light chain expression at both the mRNA and
protein levels. (A) HNE2-LMP1 cells were treated with the indicated concentrations of PD98059 or 0.1% DMSO for 2 hr. Whole cell lysates were
prepared and total and phosphorylated ERKs levels were determined by Western blotting. (B) HNE2-LMP1 cells were treated with the indicated
concentrations of PD98059 or 0.1% DMSO for 12 hr. Kappa light chain expression in NPC cells was assessed by Western blotting using a specific
antibody. (C) HNE2 and HNE2-LMP1 cells were treated with 50 mM PD98059 or 0.1% DMSO for 12 hr and Western blotting was performed to detect
kappa light chain expression. (D) HNE2 and HNE2-LMP1 cells were incubated with medium containing the indicated concentration of PD98059 or
0.1% DMSO for 12 hr. Total RNA was isolated from cells and subjected to RT-PCR, using specific primers designed to amplify kappa light chain and
actin mRNAs. (E) HNE2-LMP1 cells were transfected with si-ERK or scrambled oligonucleotide. ERK and Ig kappa protein levels were detected by
immunoblotting. The results shown are representative of three independent experiments. Phosphorylation or total expression level for each protein
as well as mRNA was estimated by densitometry and are presented as a ratio to the respective loading control (right panels). XG7 and XG6 cells are
shown as positive and negative controls, respectively, for kappa light chain.
doi:10.1371/journal.pone.0032624.g001
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pathway, Ets-1 protein expression, phosphorylation and activation
were analyzed. A higher level of Ets-1 protein expression and
phosphorylation was observed in HNE2-LMP1 cells (Figure 5A,
B), indicating that LMP1 could promote both increased expression
and phosphorylation levels of Ets-1. To examine whether LMP1-
increased expression and activation of Ets-1 were also mediated by
the ERK signaling pathway, the contribution of ERK was
evaluated through the inactivation of ERK activity. The result
showed that PD98059 reduced LMP1-induced upregulation of
Ets-1 protein expression in a dose-dependent manner (Figure 5A).
We then evaluated the phosphorylation status of Ets-1 under the
same treatments. Ets-1 proteins were immunoprecipitated and
similar levels of Ets-1 were loaded to avoid the possibility that the
differences in the protein level of Ets-1 interfere in Ets-1
phosphorylation levels [41]. Western blotting analysis of Ets-1
immunoprecipitates with a pan threonine-phospho-specific anti-
body indicated that treatment with PD98059 resulted in a
concentration-dependent inhibition of LMP1-induced Ets-1 thre-
onine phosphorylation (Figure 5B). This result corresponded with
a dose-dependent attenuation of LMP1-induced ERK phosphor-
ylation (Figure 1A) and LMP1-induced kappa light chain
expression (Figure 1B). These data indicated that ERK might
modulate activation of Ets-1 by modifying Ets-1 turnover as well as
through its phosphorylation. To further determine whether Ets-1
is involved in LMP1-induced Ig kappa expression, we evaluated
the effect of Ets-1 siRNA on Ig kappa expression in HNE2-LMP1
cells. The siRNA-mediated knockdown of Ets-1 gene expression
Figure 2. The PU binding site is involved in LMP1-induced human 39Ek enhancer activity in NPC cells. (A) Schematic diagram of the
human 39Ek core fragment-containing DNA portion used in these experiments. The position of the PU binding site is shown. For simplicity, other
protein-binding sites in the 39Ek are not shown. The expansion of the PU binding site gives its wild-type sequence and the nucleotides replaced by
mutations are underlined. Arrows indicate the nucleotides introduced by mutations. (B) Insertion sites for the DNA fragment in the pGL3-b vector,
which contains the human b-globin promoter and the luciferase reporter gene. (C) Comparison of 39Ek activity in human nasopharyngeal carcinoma
cell lines. The constructs carrying the wild-type PU sequence (pb-39Ekwt), mutant PU sequence (pb-39Ekmt), pGL3-b or pGL3-Basic with the internal
control plasmid pRL-SV40 were transiently co-transfected into HNE2 and HNE2-LMP1 cells. Luciferase reporter assays were performed as described in
‘‘Materials and methods’’. Values for firefly luciferase activity were normalized to those obtained for Renilla luciferase activity. Values obtained for cells
transfected with pb-39Ekwt, pb-39Ekmt and pGL3-b were divided by the corresponding values obtained for cells transfected with pGL3-Basic. Data are
shown as means 6 S.D. of three independent experiments performed in triplicate. Statistical significance: #p,0.05 vs. pGL3-b-transfected HNE2 cells;
*p,0.01 vs. pGL3-b-transfected HNE2-LMP1 cells; **p,0.05 vs. pb-39Ekwt-transfected HNE2-LMP1 cells.
doi:10.1371/journal.pone.0032624.g002
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we found that the knockdown of endogenous Ets-1 is accompanied
by a decrease of Ig kappa light chain expression level as compared
with control siRNA (Figure 5C), pointing to a role of Ets-1 in
kappa light chain regulation. Collectively, these findings suggest a
probable signaling pathway by which LMP1 upregulates Ig kappa
light chain expression by activating ERK to mediate Ets-1
expression and phosphorylation.
LMP1 promotes binding of the Ets-1 transcription factor
to the kPU motif in vitro
We next examined whether the DNA fragment encompassing
the PU motif of the human kappa light chain gene exhibits
transcription factor binding activity and whether LMP1 can
increase the binding through ERK signaling. Biotin-labeled
double-stranded oligonucleotide probes containing the PU motif
were used for EMSA analysis of binding in nuclear extracts from
vehicle- or PD98059-treated HNE2 and HNE2-LMP1 cells.
Results indicated that two different DNA/protein complexes (I
and II) could be observed (Figure 6A). A 100-fold excess of
unlabeled wild-type kPU probe (lane 5) successfully competed with
the formation of the complex. However, a 100-fold excess of
unlabeled mutant kPU probe (lane 6) or a non-specific NF-kB
probe (lane 7) had no effect on the binding, thus demonstrating
that both complexes were formed specifically. The nuclear lysates
isolated from these cells did not induce the formation of complex I
when a biotin-labeled mutant-type PU oligonucleotide was
introduced, whereas complex II remained (Figure 6B), thus
revealing that the Ets-related protein formed the slower migrating
complex I. Moreover, pre-incubation of nuclear extract with an
Ets-1 antibody resulted in the formation of supershifts accompa-
nied by a dose-dependent attenuation of the intensity of complex I
but no change in complex II (Figure 6C, lanes 4 and 5). The
addition of an unrelated antibody did not alter the binding
(Figure 6C, lane 6). These results indicated that the kPU site is
capable of binding the Ets-1 transcription factor in nuclear extracts
of NPC cells. We found a much higher level of complex I in
HNE2-LMP1 cells compared to the level observed in HNE2 cells
(Figure 6A, lane 2 vs. 3), which indicated that LMP1 could
substantially increase Ets-1 transcription factor binding to the PU
motif of the human 39Ek enhancer. The MEK inhibitor, PD98059
(50 mM), completely inhibited LMP1-induced Ets-1-DNA binding
activity (Figure 6A, lane 4), but did not obviously alter the binding
of PU oligonucleotide with HNE2 nuclear extract (Figure S1).
Because the PU probe used was derived from the PU sequence in
human 39Ek, we speculated that LMP1 induced the Ets-1
transcription factor to target to 39Ek through the ERKs signaling
pathway.
LMP1 promotes Ets-1 binding to PU motif of human
kappa gene in vivo
To better understand the role of the Ets-1 transcription factor in
regulating human 39Ek and kappa light chain expression in cells,
we analyzed the fragment that spans the PU binding region within
39Ek using a chromatin immunoprecipitation assay (ChIP).
HNE2-LMP1 cells were treated with 1% formaldehyde to cross-
link the proteins to chromatin and the cross-linked chromatin was
then sheared by sonication to fragments of ,500 bp in length.
The sheared cross-linked chromatin was subsequently subjected to
immunoprecipitation reactions using antibodies specific for
detecting Ets-1. An IgG antibody was used as a nonspecific
control. The precipitated chromatin DNA was then purified and
amplified by PCR using primers specific for the PU binding site of
the Ig kappa gene. The primers for the human 39Ek region
containing the PU binding site produced 158-bp amplicons that
could be observed with the positive control (input chromatin) and
when the chromatin was precipitated with antibodies specific for
Ets-1 (Figure 7). No amplification was observed with three
negative controls (no chromatin, no antibody, and IgG).
Therefore, the ChIP results indicated that the Ets-1 transcription
factor can exert its regulatory function through direct binding to
the human 39Ek enhancer and finally upregulating the kappa light
chain expression in NPC cells. Overall, the results suggested that
the interaction of Ets-1 with the PU binding site of the human Ig
kappa gene might be a key event in the upregulation of kappa light
chain expression by LMP1 in NPC cells.
Discussion
The expression of Igs is widespread in epithelial cancers from
many organs and basically includes all kinds of isotypes. Among
the heavy chain class, the a chain for IgA and the c chain for IgG
were the most prevalent, whereas the k, but not the l, light chain
was confirmed to be present. In our previous and present studies,
we confirmed the aberrant expression of the Ig kappa light chain
in NPC cells. Moreover, several studies indicated that tumor-
derived Igs have certain biological functions. Qiu [4] found that
blockade of tumor-derived IgG, expressing kappa light chain,
using either antisense oligodeoxynucleotide or anti-human IgG,
induced cancer cell apoptosis and inhibited cancer growth. This
therefore confirmed that IgG secreted by epithelial cancers had
some unidentified capacity to promote the growth and survival of
tumor cells. We also found that obstruction of cancer-derived Ig
alpha suppressed the growth and viability of cancer cells.
Furthermore, we demonstrated that cancer-derived Ig alpha
promotes the malignant proliferation ability of cancer cells and
Figure 3. The MEK inhibitor, PD98059, abolishes the LMP1-
increased 39Ek enhancer activity. HNE2 and HNE2-LMP1 cells were
co-transfected with pb-39Ekwt, pGL3-b, or pGL3-Basic and the internal
control pRL-SV40 plasmids. Cells were incubated for 24 hr and then
treated with PD98059 (50 mM) or DMSO (0.1%) for an additional 12 hr
after which activity of firefly and Renilla luciferase was monitored as
described in ‘‘Materials and Methods’’. Values for firefly luciferase
activity were normalized to those obtained for Renilla luciferase activity.
Values obtained for pb-39Ekwt- or pGL3-b-transfected cells were divided
by the corresponding values obtained for pGL3-Basic-transfected cells.
Data are shown as means 6 S.D. of three independent experiments
performed in triplicate. Statistical significance: *p,0.05.
doi:10.1371/journal.pone.0032624.g003
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synchronized cancer cells [42]. These findings support an
important role for cancer-derived Ig as a growth factor of cancer
cells. In addition, we found that the expression of kappa constant
region mRNA was markedly increased in uterine cervical epithelia
with dysplasia and carcinoma, as compared with cervicitis, thus
suggesting a close association of kappa light chain expression with
cell malignancy and with increasing tumor grades [1]. The fact
that different research groups reported that nonlymphoid cells
express Igs and the potential biological functions of the tumor-
derived Igs suggests that this phenomenon is not a chance event.
However, the mechanisms underlying the expression of Igs in
nonlymphoid cells are still unknown. In the present study, we used
Ig kappa-expressing NPC cell lines as models and focused mainly
on exploring the possible mechanisms by which nonlymphoid cells
express Ig kappa. We demonstrated that LMP1 promotes active
Ets-1 binding to 39Ek that is mediated through the ERK signaling
pathway, thus contributing to kappa light chain upregulation in
Figure 4. ETS family gene expression in human NPC cells. (A)Total RNA was isolated from HNE2, HNE2-LMP1 and Raji cells and the expression
of ETS family members at the mRNA level was analyzed by RT-PCR. The B-cell lineage Raji cell line was used as a control. GAPDH was used as an
internal control. (B) mRNA expression levels for Ets-1, Ets-2, E1AF and ERM in HNE2 and HNE2-LMP1 cells were analyzed by quantitative real-time RT-
PCR. The level of each mRNA from HNE2 was normalized to a value of 1. Fold-change in mRNA levels is shown. Values are presented as the mean 6
S.D of two independent experiments performed in triplicate. Statistical significance: *p,0.01, **p,0.001.
doi:10.1371/journal.pone.0032624.g004
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e32624Figure 5. Inhibition of ERKs signaling reduces LMP1-induced Ets-1 expression and phosphorylation. (A) Inhibition of LMP1-upregulated
Ets-1 protein expression by the MEK inhibitor, PD98059. HNE2-LMP1 cells were treated with the indicated concentrations of PD98059 or 0.1% DMSO
for 12 hr. Ets-1 expression in NPC cells was determined by Western blot. A representive image of three independent experiments with similar results
and the Ets-1 expression level quantified by densitometry are shown. a-Tubulin was used to verify equal protein loading. (B) Inhibition of threonine
phosphorylation of Ets-1 by the MEK inhibitor, PD98059. NPC cells were treated with the indicated concentrations of PD98059 for 12 hr and whole
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role of immunoglobulins produced in LMP1-positive human
epithelial cancer cells.
The activation of kappa enhancers, whose function is mediated
by proteins binding to the enhancers, is required for Ig kappa gene
expression [43,44,45]. We found that 39Ek is active in both LMP1-
negative and LMP1-positive NPC cells. In LMP1-negative HNE2
cells, the 39Ek activity is relatively small, which corresponds with
the low kappa expression level. LMP1 can further stimulate 39Ek
activity and contributes to the upregulation of Ig kappa in NPC
cells. Our results indicated that mutation of the PU biding site did
not completely abolish LMP1-induced 39Ek activity and only
cell extracts were immunoprecipitated with an anti-Ets-1 antibody. Similar protein levels of Ets-1 were loaded and resolved by SDS-PAGE, and the
levels of Ets-1 threonine phosphorylation were determined by Western blot analysis using a pan threonine phosphorylation antibody. The membrane
was then stripped and reprobed with anti-Ets-1. The threonine phosphorylation level of Ets-1 was quantified by densitometry. (C) HNE2-LMP1 cells
were transfected with si-Ets-1 or scrambled oligonucleotide. Ets-1 and Ig kappa protein levels were detected by immunoblotting. The results shown
are representative of three independent experiments. Phosphorylation or expression level for each protein was estimated by densitometry and was
presented as a ratio to the respective loading control (right panels).
doi:10.1371/journal.pone.0032624.g005
Figure 6. LMP1 enhances the binding ability of the Ets-1 transcription factor to human 39Ek enhancer through the ERKs signaling
pathway in vitro. (A) A biotin-labeled wild-type kPU oligonucleotide probe was incubated with nuclear extracts of HNE2, HNE2-LMP1 and PD98059-
treated HNE2-LMP1 cells (50 mM for 12 hr) in the presence of a 100-fold excess of unlabeled wild-type kPU (lane 5), a 100-fold excess of unlabeled
mutant kPU oligonucleotide (designated mut PU, lane 6), or a non-specific competitor (NS, kNF-kB probe, lane 7). Protein-DNA binding activities
were then examined by EMSA. (B) A biotin-labeled mutant kPU oligonucleotide probe was incubated with nuclear extracts of various NPC cell lines,
and then protein DNA-binding activities were examined by EMSA. (C) In the binding assays, an Ets-1 antibody was preincubated with nuclear extracts
from HNE2-LMP1 cells before the addition of the biotin-labeled wild-type kPU oligonucleotide probe. Super-EMSA was then performed. Protein-DNA
complexes are indicated as I and II. See Materials and methods for the sequence details of the probes used.
doi:10.1371/journal.pone.0032624.g006
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addition to the PU motif in human 39Ek that modulates enhancer
activity, the 39Ek enhancer region also comprises several putative
sequences, including the kB motif, the interferon response
element, CRE, PIP and E-box motifs for which functions have
not yet been demonstrated. These sequences could potentially
regulate 39Ek activity [10,11]. Therefore, in addition to the Ets
family proteins, other transcription factors binding to the 39Ek
enhancer region mediated through various signaling pathways to
regulate kappa expression in NPC cells cannot be excluded at this
time.
By gel shift analysis, we found that the transcription factor Ets-1
bound to the kPU motif in NPC cells. The expression patterns of
Ets family proteins are variable. Some are expressed ubiquitously,
whereas others are expressed in a tissue-specific manner [15]. For
example, PU.1 is exclusively expressed in hematopoietic cells [18].
In pre-B and B cells, PU.1 has been implicated in regulating the
activities of enhancers and promoters in many B cell specific genes,
including the immunoglobulin kappa gene. Intriguingly, the transcrip-
tion factor Spi-C (Prf), which is closely related to PU.1 and Spi-B,
can occupy PU binding sites [46]. An in vitro binding study
demonstrated that two Ets family members, Ets-1 and Elf-l, could
bind to the PU motif within 39Ek [47]. By investigating the
endogenous ETS proteins Ets-1, Elf-1, and GABPa in a human T-
cell line, Graves [19] discovered that these divergent family
members frequently occupied the same genomic regions. The
finding suggested that other Ets-related proteins were capable of
binding to the PU site and contributed to kappa gene expression. In
effect, our EMSA results demonstrated that, in NPC cells, the
transcription factor Ets-1, but not PU.1, bound to the PU
consensus sequences within the 39Ek. In the absence of PU.1 in
NPC cells, transcription factor Ets-1 might be more likely to
compensate for the loss of PU.1 and occupy the PU binding site as
well as play an important role in upregulating kappa gene
expression. LMP1 also increased the mRNA levels of E1AF and
ERM, members of the PEA3 subfamily of Ets transcription factors
(Figure 4A, B). Whether or not they play a role in upregulating
kappa gene expression in NPC cells remains to be elucidated.
Additionally, our studies did not evaluate the phosphorylation
status of other Ets family proteins in HNE2 and HNE2-LMP1 cell
lines, and the possibility cannot be excluded that the phosphor-
ylation levels but not expression levels of these proteins induced by
LMP1, is involved in upregulating kappa gene expression in NPC
cells.
We found that incubating the labeled kPU probe with nuclear
extracts of NPC cells produced two protein-DNA complexes (I and
II) (Figure 6). The kPU probes used in our experiments contained
a wild-type IRF motif (GAAAAC) [48], which is located 2 bp
downstream from the kPU motif. These two motifs form an Ets-
IRF composite element (EICE), which has been identified in not
only the Igk, but also the Igl, IL-1b enhancers, CD20, gp91
phox, and
toll-like receptor 4 (TLR4) promoters, and play an important role in
gene regulation [49,50]. The IRF transcription factor family
comprises at least ten members. The expression of IRF-1, IRF-2,
IRF-3, IRF-7 and IRF-9 is ubiquitous but IRF-4 and IRF-8 are
thought to be expressed exclusively in cells of macrophage and
lymphocyte lineages [50]. PU.1 was reported to interact with
either IRF-4 or IRF-8 at the EICE element, resulting in
transcriptional activation. IRF-4 can form ternary complexes on
EICE with PU.1 or with another Ets-related factor, Spi-B [49].
IRF-8 can also form transcriptional complexes on EICE in a
PU.1- or Spi-B-dependent manner [51,52,53]. These observations
suggested that the complexes formed by Ets and IRF family
members, which bind to the EICE element, might have great
diversity. Our EMSA experiments indicate that Ets-1 can bind to
the EICE element and complex I was, in effect, composed of two
EMSA bands (Figure 6C) and the addition of anti-Ets-1 attenuated
these two bands (Figure 6C, lanes 4 and 5). Therefore, we propose
that Ets-1/DNA and Ets-1/IRFs/DNA complexes might exist.
When assayed with a labeled mutant kPU probe, the whole
complex I disappeared completely, which might be due to the
failure of Ets-1 binding to the mutant kPU probe to form the Ets-
1/DNA and Ets-1/IRFs/DNA complexes. Notably, in the mutant
kPU probe, the wild-type IRF motif remained intact, which was in
accordance with the observation that complex II was unaffected.
We therefore speculated that the complex II might be an IRFs/
DNA complex. In B cells, the PU.1/IRF-4 transcription factor
complex binding to the kappa EICE element plays an important
role in kappa gene regulation. However, the lack of haematopoietic
cell lineage-specific transcription factors, PU.1 and IRF-4, in NPC
cell lines, combined with our EMSA results leads us to speculate
that the transcription factor Ets-1 might cooperate with other IRFs
to bind the EICE element of the 39Ek to modulate kappa gene
expression in a manner different from B cell lines. However, what
kind of IRFs involved in forming the Ets-1/IRFs/DNA complexes
and the mechanism by which Ets-1 interacts with IRFs as well as
how these interactions relate to the control of 39Ek function in
NPC cells will require further studies.
Expression of the kappa light chain in cancer cells is
complicated. Not only the NPC cell lines, but many human
epithelial cancer cell lines, including MCF-7 (breast carcinoma),
HeLa (cervical carcinoma), MGC (gastric carcinoma), SW480
(colon carcinoma), and A549 (lung cancer) cells, express kappa
light chain [1,4]. Several infectious agents, particularly viruses, can
encode oncoproteins, such as EBV-encoded LMP1, HBV-encoded
X protein, HCV-encoded Core protein, HPV-encoded E6 and E7
proteins, have been identified as causes of cancer [54]. In NPC,
LMP1 is considered to be a major oncogenic protein encoded by
EBV and can aberrantly activate many signaling pathways.
Similar to LMP1, other virus-encoded oncoproteins, including
HBX, E6, and E7, might also be able to induce immunoglobulin gene
Figure 7. The transcription factor Ets-1 interacts with the
human Ig kappa 39 enhancer in cells. ChIP analysis of the PU
binding site within the 39 enhancer in HNE2-LMP1 cells. The cross-linked
chromatin was precipitated with an Ets-1 antibody. The positive control
is represented by the input fraction. Negative controls included a no
chromatin sample, no antibody sample, and a nonspecific antibody
(aIgG) sample. Precipitated DNA was analyzed by PCR using primers
that amplified a 158-bp region, which included the PU binding site.
doi:10.1371/journal.pone.0032624.g007
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corresponding transcription factors and signaling pathways. The
present study, using the NPC cell lines as models, provides some
hints of possible mechanisms by which human cancer cells of
epithelial origin produce immunoglobulins and lay the foundation
for further studies.
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Figure S1 Effect of ERK inhibitor PD98059 on the
binding ability of the Ets-1 transcription factor to
human 39Ek enhancer in HNE2 cells in vitro. A biotin-
labeled wild-type kPU oligonucleotide probe was incubated with
nuclear extracts of vehicle- or PD98059-treated HNE2 cells
(50 mM for 12 hr) in the presence of a 100-fold excess of unlabeled
wild-type kPU (lane 4), a 100-fold excess of unlabeled mutant kPU
oligonucleotide (mutPU, lane 5), or a non-specific competitor (NS,
kNF-kB probe, lane 6). Protein-DNA binding activities were then
examined by EMSA. See Materials and methods for the sequence
details of the probes used.
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Table S1 Primers used for amplification of human Ig
kappa light chain, Ets family members and LMP1.
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